| Title |
Methotrexate for treating rheumatoid arthritis
|
|---|---|
| Published in |
Cochrane database of systematic reviews, June 2014
|
| DOI | 10.1002/14651858.cd000957.pub2 |
| Pubmed ID | |
| Authors |
Maria Angeles Lopez-Olivo, Harish R Siddhanamatha, Beverley Shea, Peter Tugwell, George A Wells, Maria E Suarez-Almazor |
| Abstract |
Methotrexate is a folic acid antagonist widely used for the treatment of neoplastic disorders. Methotrexate inhibits the synthesis of deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins by binding to dihydrofolate reductase. Currently, methotrexate is among the most commonly used drugs for the treatment of rheumatoid arthritis (RA). This is an update of the previous Cochrane systematic review published in 1997. |
X Demographics
The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 2 | 20% |
| Germany | 1 | 10% |
| Spain | 1 | 10% |
| United Kingdom | 1 | 10% |
| Ecuador | 1 | 10% |
| Unknown | 4 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 8 | 80% |
| Science communicators (journalists, bloggers, editors) | 1 | 10% |
| Practitioners (doctors, other healthcare professionals) | 1 | 10% |
Mendeley readers
The data shown below were compiled from readership statistics for 483 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 3 | <1% |
| Switzerland | 1 | <1% |
| Brazil | 1 | <1% |
| Pakistan | 1 | <1% |
| South Africa | 1 | <1% |
| Spain | 1 | <1% |
| Unknown | 475 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 69 | 14% |
| Researcher | 53 | 11% |
| Student > Bachelor | 51 | 11% |
| Student > Ph. D. Student | 48 | 10% |
| Student > Postgraduate | 32 | 7% |
| Other | 98 | 20% |
| Unknown | 132 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 180 | 37% |
| Nursing and Health Professions | 29 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 28 | 6% |
| Biochemistry, Genetics and Molecular Biology | 19 | 4% |
| Agricultural and Biological Sciences | 16 | 3% |
| Other | 64 | 13% |
| Unknown | 147 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 24. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 November 2023.
All research outputs
#1,500,141
of 24,829,155 outputs
Outputs from Cochrane database of systematic reviews
#3,294
of 12,983 outputs
Outputs of similar age
#14,768
of 234,548 outputs
Outputs of similar age from Cochrane database of systematic reviews
#57
of 237 outputs
Altmetric has tracked 24,829,155 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,983 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.0. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 234,548 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 237 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.